WELCOME TO

Specialist Communications for Life Sciences
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Our
Services
Focused on supporting life science companies to raise their profile, build corporate value, and generate interest, the services we provide include:
PR & Media
- Press releases
- Article writing and placement
- Media interviews
- Messaging
- Copy writing
- Social media
- Media training
- Events
Marketing
- Conference, event and trade show support
- Marketing literature
- Market research
- Campaign development
- Advertising
- Sponsorship
- Product launches
Design & Branding
- Website design and development
- Print collateral development
- Identity and logo creation
- Brand strategy
- Presentation development
- Video production
Investor Relations
- Business plan development
- Presentation development
- PR targeting the life science trade press read by investors

The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
JPM Healthcare Conference
-
OBN Bioseed 2026
-
PepTalk – The Protein Science and Production Week
-
Festival of Genomics and Biodata
CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing
Collaboration formed to accelerate biopharmaceutical manufacturing combining high performing CHO-MK cells and GMP-manufactured culture media KAWASAKI, Japan and SANTA ANA, California. USA, 18 December, 2025 - Chitose Laboratory Corp., (CHITOSE), [...]
Atelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models
Partnership brings together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in preclinical research and biotech sectors Newcastle, UK, 15th December 2025: Atelerix, a biotech company [...]
EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy
Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory epilepsy (FRE) Future financings [...]




















